Predicting risk of major adverse cardiac events

Details Predicting risk of major adverse cardiac events Predicting risk of major adverse cardiac events

G - Physics

01

N

G01N 33/50 (2006.01) C12Q 1/68 (2006.01) G01N 33/68 (2006.01)

Patent

CA 2720674

Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.

Linvention concerne la mesure des concentrations de ST2 et de peptide natriurétique en circulation (p. ex. NT-proBNP), qui est utile pour lévaluation pronostique de sujets, notamment pour la prédiction de résultats cliniques indésirables, p. ex. la mortalité, la transplantation et linsuffisance cardiaque.

Affiliated with

Also associated with

Rating

Predicting risk of major adverse cardiac events does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Predicting risk of major adverse cardiac events, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Predicting risk of major adverse cardiac events will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2062736